19
2018
Artificial intelligence, machine learning and big data

Timo Minssen , Claudia Seitz
EUROPEAN PHARMACEUTICAL LAW REVIEW 3 ( 4)

2019
Nudges or Shoves in the Secondary Use of Health Data: What is the More Desirable Approach? (Part I)

Timo Minssen , Janos Meszaros , Marcelo Corrales Compagnucci
Harvard Law School's Bill of Health blog

2019
Reconciling IPRs and openness in biobanking

Timo Minssen , Isabelle Huys , Michiel Verlinden
European Intellectual Property Review 38 ( 1) 1 -4

2016
Preparing for antimicrobial resistance in the wake of the COVID-19 pandemic: The vision and “social science” mission of the INAMRSS network

Francesco Ciabuschi , Kevin Outterson , Timo Minssen , Ramanan Laxminarayan
Harvard Law School's Bill of Health blog

2020
Contribution to case law summaries and comments: Tri-lingual

Timo Minssen
European Patent Office Munich

2011
Clearing a way through the CRISPR patent jungle

Esther Van Zimmeren , Timo Minssen , Jakob Wested
Life Sciences Intellectual Property Review (LSIPR)

2018
2
2015
Big Data and Intellectual Property Rights in the Health and Life Sciences

Timo Minssen , Justin Pierce
Social Science Research Network

11
2018
AIPPI Report for Denmark on Plausibility in Patent Law: AIPPI 2019 - 2019 Study Questions - Plausibility

Timo Minssen , Ulla Callesen Klinge , Mikkel Vittrup , Sture Rygaard

2019
Is Data Sharing Caring Enough About Patient Privacy?: Part I: The Background

Timo Minssen , Carmel Shachar , Sara Gerke
Harvard Law School's Bill of Health blog

2019
Standardization, IPRs and open innovation in synthetic biology

Timo Minssen , Jakob B. Wested
Chapters 34 -66

2015
Evolving Biosimilar Clinical Requirements: A Qualitative Interview Study with Industry Experts and European National Medicines Agency Regulators

Anna Birna Almarsdóttir , Timo Minssen , Marie Louise De Bruin , Marie Louise De Bruin
BioDrugs 35 ( 3) 351 -361

2021